Navigation Links
Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
Date:12/22/2011

CAMBRIDGE, Mass., Dec. 22, 2011 /PRNewswire/ -- Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, has reported a method for detecting individual proteins within microfabricated polymer arrays produced by Sony DADC.  Quanterix recently entered into a collaboration with Sony DADC for the development and manufacture of "smart consumables" based on an optical disc format.  This method was published online in Lab on a Chip.

"We have developed a device that enables the fluidic sealing and isolation of single molecules in arrays containing hundreds of thousands of miniaturized wells.  These consumables are manufactured using high precision and high volume manufacturing processes, and will be at the heart of the SiMoA instrument that we are currently developing.  By using arrays enclosed in microfluidic channels we are able to perform SiMoA in a fully automated fashion," said David Duffy, Ph.D., Vice President of Research at Quanterix and corresponding author of the publication. "This represents a significant milestone towards our goal of developing an automated platform that enables single molecule sensitivity while offering significant advantages for the manufacture of high quality, low-cost consumables.  These devices will facilitate high throughput and sensitive detection of biomarkers, and address important applications in life science research and in vitro diagnostics."

Martin Madaus, Ph.D., Quanterix Chairman and CEO added, "This achievement is an important step towards our goal to commercialize the SiMoA technology.  Working closely with our strategic partners, Quanterix plans to develop and manufacture a fully automated instrument for its SiMoA technology that will utilize these consumables to support a menu of diagnostic tests.  Quanterix expects to launch the life science instrument in 2013, followed by an IVD platform to be commercialized in 2014."

About Quanterix

Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today's analog only technology. SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring. Automated systems based on SiMoA will provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness.  Founded in 2007, the privately held Cambridge, Massachusetts-based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit www.quanterix.com.

 


'/>"/>
SOURCE Quanterix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
2. Quanterix Fifth-Generation PSA Test Enables More Sensitive Measurements Following Surgery
3. Quanterix PSA Test Found to be a Reliable Predictor of Prostate Cancer Recurrence Following Surgery
4. Quanterix Digital ELISA Measures Low Abundance Biomarkers of Inflammation in Crohns Disease
5. Quanterix and STRATEC Announce Strategic Partnership
6. Quanterix Announces Publication of Novel Method Expanding Single Molecule Detection Capability
7. Quanterix Announces New Technology Evaluation Agreement
8. Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board
9. Ecology Coatings Develops Coatings Safe for Direct Contact with Food Products
10. UCLA team develops highly efficient method for creating flexible, transparent electrodes
11. NASA develops super-black material that absorbs light across multiple wavelength bands
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):